The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
Breast Neoplasms
/ diagnosis
Community Health Services
/ methods
Exercise Therapy
Female
Follow-Up Studies
Home Care Services
/ statistics & numerical data
Humans
Life Style
Middle Aged
Obesity
/ therapy
Overweight
/ therapy
Patient Education as Topic
Prognosis
Quality of Life
Weight Gain
Weight Loss
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
22
08
2018
accepted:
28
06
2019
revised:
19
06
2019
pubmed:
2
8
2019
medline:
28
5
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight women. Overweight or obese (n = 243) and normal weight (n = 166) women were randomised to a three-month unsupervised home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes. Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control mean (95% CI); weight -2.3 (-3.5, -1.0) kg, body fat -1.6 (-2.6, -0.7) kg, community vs. control; weight -2.4 (-3.6, -1.1) kg, body fat -1.4 (-2.4, -0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective. The programmes were equally effective for weight control, but the community programme had additional benefits. ISRCTN68576140.
Sections du résumé
BACKGROUND
Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight women.
METHODS
Overweight or obese (n = 243) and normal weight (n = 166) women were randomised to a three-month unsupervised home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes.
RESULTS
Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control mean (95% CI); weight -2.3 (-3.5, -1.0) kg, body fat -1.6 (-2.6, -0.7) kg, community vs. control; weight -2.4 (-3.6, -1.1) kg, body fat -1.4 (-2.4, -0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective.
CONCLUSIONS
The programmes were equally effective for weight control, but the community programme had additional benefits.
CLINICAL TRIAL REGISTRATION
ISRCTN68576140.
Identifiants
pubmed: 31366999
doi: 10.1038/s41416-019-0522-6
pii: 10.1038/s41416-019-0522-6
pmc: PMC6738088
doi:
Banques de données
ISRCTN
['ISRCTN68576140']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-454Subventions
Organisme : Department of Health
ID : PB-PG-0407-12313
Pays : United Kingdom
Organisme : Department of Health
ID : IS-BRC-1215-20007
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
J Clin Oncol. 2016 Mar 1;34(7):669-76
pubmed: 26598750
J Clin Oncol. 1997 Mar;15(3):974-86
pubmed: 9060536
Cancer Causes Control. 2008 Dec;19(10):1319-28
pubmed: 18752034
Health Econ. 1996 Mar-Apr;5(2):141-54
pubmed: 8733106
BMC Cancer. 2017 Dec 18;17(1):863
pubmed: 29254480
Breast Cancer Res Treat. 2010 Nov;124(1):205-11
pubmed: 20182796
Patient Educ Couns. 2016 Jul;99(7):1220-1226
pubmed: 26860549
BMJ Open. 2017 Mar 6;7(3):e012187
pubmed: 28264824
Br J Sports Med. 1999 Aug;33(4):244-9
pubmed: 10450478
Clin Breast Cancer. 2018 Apr;18(2):175-183
pubmed: 29598955
Open Obes J. 2011;3:87-97
pubmed: 22238561
Sports Med. 2004;34(5):307-16
pubmed: 15107009
Br J Gen Pract. 2012 Dec;62(605):664-6
pubmed: 23211256
Br J Nutr. 2013 Oct;110(8):1534-47
pubmed: 23591120
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Prev Med. 2017 Jul;100:194-207
pubmed: 28456513
Breast Cancer Res Treat. 1998 Mar;48(1):53-64
pubmed: 9541189
PLoS One. 2015 Jun 01;10(6):e0127520
pubmed: 26029921
Psychol Health. 2011 Nov;26(11):1479-98
pubmed: 21678185
Breast Cancer Res Treat. 2012 Sep;135(2):581-9
pubmed: 22869285
J Clin Oncol. 2016 Dec 10;34(35):4284-4294
pubmed: 27903151
Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38
pubmed: 24222017
Clin Breast Cancer. 2008 Feb;8(1):70-9
pubmed: 18501061
J Diabetes Metab Disord. 2015 Apr 17;14:31
pubmed: 25973403
Int J Cancer. 2016 May 1;138(9):2088-97
pubmed: 26606746
Curr Atheroscler Rep. 2014 Oct;16(10):442
pubmed: 25092578
Clin J Oncol Nurs. 2014;18 Suppl:15-22
pubmed: 24480658
J Clin Oncol. 2005 Aug 20;23(24):5814-30
pubmed: 16043830
Cochrane Database Syst Rev. 2017 Aug 24;8:CD011152
pubmed: 28836379
J Clin Oncol. 2016 Mar 1;34(7):646-8
pubmed: 26712225
World J Clin Oncol. 2014 Aug 10;5(3):272-82
pubmed: 25114844
Obes Rev. 2014 Sep;15(9):749-68
pubmed: 24891269
Psychooncology. 2015 Oct;24(10):1250-1257
pubmed: 26060053
J Rehabil Med. 2015 Oct 5;47(9):801-8
pubmed: 26435098
Curr Breast Cancer Rep. 2013 Sep;5(3):222-246
pubmed: 26605003
Breast. 2017 Apr;32:144-155
pubmed: 28189100
J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76
pubmed: 17179478
JAMA Oncol. 2018 Jun 1;4(6):798-804
pubmed: 29621380
Integr Cancer Ther. 2018 Mar;17(1):131-137
pubmed: 28110564
J Sports Sci. 2012 May;30(9):949-52
pubmed: 22506482
Acta Oncol. 2015 May;54(5):635-54
pubmed: 25752971
Breast Cancer Res Treat. 2010 Nov;124(1):163-75
pubmed: 20734132
J Clin Oncol. 2015 Jun 10;33(17):1918-27
pubmed: 25918291
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1540-3
pubmed: 10556117
Cochrane Database Syst Rev. 2017 Jun 30;6:CD007130
pubmed: 28665511
J Natl Cancer Inst. 2015 Sep 30;107(12):djv275
pubmed: 26424778
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Cancer Surviv. 2013 Mar;7(1):74-82
pubmed: 23179496
Int J Obes (Lond). 2011 May;35(5):714-27
pubmed: 20921964
Support Care Cancer. 2015 Jan;23(1):159-67
pubmed: 25022760
J Cancer Surviv. 2015 Dec;9(4):660-82
pubmed: 25757733
Cancer Treat Rev. 2018 Sep;69:188-203
pubmed: 30077954
J Clin Oncol. 2014 Jul 20;32(21):2231-9
pubmed: 24934783
Health Econ. 2004 May;13(5):437-52
pubmed: 15127424
Behav Sci (Basel). 2017 Jan 19;7(1):
pubmed: 28106818
Eur J Cancer. 2015 Apr;51(6):705-20
pubmed: 25747851
J Clin Oncol. 2016 Sep 10;34(26):3157-65
pubmed: 27458291